Public Health
123:207–212PubMedCrossRef Commission on Chronic Illness (1957) Chronic illness in the United States, vol 1. Harvard University Press, Cambridge European Society of Human Genetics (2010) Statement of the ESHG on direct-to-consumer genetic testing for health-related purposes. Eur J Hum Genet 18:1271–1273CrossRef Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group (2011) Recommendations from the EGAPP Working Group: routine testing for factor V Leiden (R506Q) and prothrombin (20210G>A) mutations in Vorinostat concentration adults with a history of idiopathic venous thromboembolism and their adult family members. Genet Med 13:67–76 Grosse SD, Rogowski WH, Ross LF, Cornel MC, Dondorp WJ, Khoury MJ (2010) Population screening for genetic disorders in Tucidinostat cost the 21st century: evidence, economics, and ethics. Public Health Genomics 13:106–115PubMedCrossRef Health Council
of the Netherlands (2010). Neonatal screening for cystic fibrosis. The Hague: Health Council of the Netherlands. Publication no. 2010/01E. Available at www.gezondheidsraad.nl/sites/default/files/201001E.pdf. Accessed 4 Jun 2011 Health Council of the Netherlands (2005). Neonatal screening. The Hague: Health Council VS-4718 supplier of the Netherlands. Publication no. 2005/11. Available at www.gezondheidsraad.nl/sites/default/files/05@11E.pdf. Accessed 4 Jun 2011 Health Council of the Netherlands (2008). Screening: between hope and hype. The Hague: Health Council of the Netherlands. Publication no. 2008/05E. Available at www.gezondheidsraad.nl/sites/default/files/200805E_0.pdf. Accessed 4 Jun 2011 Hofmann BM (2008) Why ethics should be part of health technology assessment. Int J Technol Assess Health Care 24(4):423–429PubMedCrossRef Kroese M, Burton H, Whittaker J, Lakshman R, Alberg C (2010) A framework for the prioritization of investment in the provision of genetic tests. Public Health Genomics 13(7–8):538–543PubMedCrossRef Mayntz R (2003) New challenges to governance theory. In: Bang HP (ed) Governance as social and political communication. Manchester University
Press, Manchester, pp 27–40 Ransohoff DF, McNaughton mafosfamide CM, Fowler FJ (2002) Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback. Am J Med 113:663–667PubMedCrossRef Schmidt H (2007) Personal responsibility for health-developments under the German Healthcare Reform 2007. Eur J Health Law 14:241–250PubMedCrossRef Schmidtke J, Cassiman JJ (2010) The EuroGentest clinical utility gene cards. Eur J Hum Genet 18(9):1068PubMedCrossRef Schwartz LM, Woloshin S, Fowler FJ Jr, Welch HG (2004) Enthusiasm for cancer screening in the United States. JAMA 291:71–78PubMedCrossRef Van El CG, Cornel MC (2011) Genetic testing and common disorders in a public health framework. Recommendations of the European Society of Human Genetics.